Five Prime Therapeutics (NASDAQ:FPRX)

CAPS Rating: 3 out of 5

Results 1 - 5 of 5

Recs

0
Member Avatar icanpickm (98.77) Submitted: 4/14/2016 4:41:21 PM : Outperform Start Price: $42.81 FPRX Score: +10.17

I haven't seen this kind of unique potential in many years. With 1.3 billion market cap, 500 million in cash. A recent 350 million licensing deal with BMY validates their science in my opinion. Their solution is not tied to one cancer or any one method of attack. Its making a new high in light of a shakey biotech sector. The market is agreeing with me for now.

Recs

0
Member Avatar usubanas2 (49.32) Submitted: 11/17/2015 1:57:40 AM : Underperform Start Price: $34.34 FPRX Score: -38.42

Close to a billion with very early stage compounds and with positive catalyst already played out, Will come down short term.

Recs

0
Member Avatar sullyz0r (32.80) Submitted: 11/26/2014 10:42:42 AM : Outperform Start Price: $20.78 FPRX Score: +129.51

I've liked FPRX for a while. Entering this as my "rich get richer" pick, along with $AGIO

Recs

0
Member Avatar pchop123 (80.73) Submitted: 8/7/2014 11:29:31 AM : Outperform Start Price: $12.14 FPRX Score: +284.56

time for a substantial rebound

Recs

2
Member Avatar zzlangerhans (99.78) Submitted: 4/8/2014 12:24:43 AM : Outperform Start Price: $16.18 FPRX Score: +182.35

Given the market cap inflation that has accompanied oncology IPO's since mid 2013, it's a little incongruous to see an outfit like Five Prime with a market cap under 350M. A quick overview doesn't indicate any obvious reason for the weak valuation. The company has a partnership with GSK for FP-1039 extracellular ligand trap which is already in clinical development, along with a recently announced partnership with Bristol Myers on preclinical immuno-oncology candidates. The latter collaboration was accompanied by a 20M upfront payment, a fairly respectable sum just for use of Five Prime's drug discovery platform. The 62M IPO last September was also solid, if not a blockbuster.

Despite their apparent undervaluation when compared to the rest of the oncology IPO class of 2013, Five Prime doesn't have any late stage pipeline candidates and therefore has a great deal to prove. However, zzporte has decided to follow up recent successful ventures with Stemline and Agios with a starter 200 share position in Five Prime at 16.64.

Results 1 - 5 of 5

Featured Broker Partners